Loading Rate of Exogenous and Autoantigenic Determinants on Major Histocompatibility Complex Class II Mediates Resistance to Multiple Sclerosis
- Авторы: Mamedov A.E.1, Zakharova M.Y.1,2, Favorova O.O.2, Kulakova O.G.2, Boyko A.N.2, Knorre V.D.1, Vorobieva N.A.3, Khurs E.N.4, Kiselev I.S.2, Baulina N.M.2, Gabibov A.G.1,5, Belogurov A.A.1,5
-
Учреждения:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
- Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
- Institute of Gene Biology, Russian Academy of Sciences
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Biological Faculty, Moscow State University
- Выпуск: Том 485, № 1 (2019)
- Страницы: 115-118
- Раздел: Biochemistry, Biophysics, and Molecular Biology
- URL: https://journals.rcsi.science/1607-6729/article/view/212897
- DOI: https://doi.org/10.1134/S1607672919020078
- ID: 212897
Цитировать
Аннотация
Genetic analysis of thousands of patients with multiple sclerosis (MS) and healthy Russian donors showed that the carriage of groups of HLA-DRB1*15 and HLA-DRB1*03 alleles is associated with the risk of MS, whereas the carriage of groups of HLA-DRB1*01 and HLA-DRB1*11 alleles is protective. Recombinant HLA-DRB1*01:01 with a high affinity can recognize the fragments of myelin basic protein (MBP), one of the autoantigens in MS. However, the comparison of the kinetic parameters of the load of MBP and viral HA peptides on HLA-DRB1*01:01, which is catalyzed by HLA-DM, showed a significantly lower rate of exchange of CLIP for MBP peptides. We assume that the observed protective properties of the group of HLA-DRB1*01 alleles may be directly associated with the ability of HLA-DRB1*01:01 to kinetically distinguish peptides of exogenous and endogenous nature.
Об авторах
A. Mamedov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Автор, ответственный за переписку.
Email: bioaz12@gmail.com
Россия, Moscow, 117997
M. Zakharova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
Email: vera.knorre@gmail.com
Россия, Moscow, 117997; Moscow, 117997
O. Favorova
Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
Email: vera.knorre@gmail.com
Россия, Moscow, 117997
O. Kulakova
Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
Email: vera.knorre@gmail.com
Россия, Moscow, 117997
A. Boyko
Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
Email: vera.knorre@gmail.com
Россия, Moscow, 117997
V. Knorre
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Автор, ответственный за переписку.
Email: vera.knorre@gmail.com
Россия, Moscow, 117997
N. Vorobieva
Institute of Gene Biology, Russian Academy of Sciences
Email: vera.knorre@gmail.com
Россия, Moscow, 119334
E. Khurs
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: vera.knorre@gmail.com
Россия, Moscow, 119991
I. Kiselev
Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
Email: vera.knorre@gmail.com
Россия, Moscow, 117997
N. Baulina
Pirogov Russian National Research Medical University, Ministry of Healthcare of the Russian Federation
Email: vera.knorre@gmail.com
Россия, Moscow, 117997
A. Gabibov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Biological Faculty, Moscow State University
Email: vera.knorre@gmail.com
Россия, Moscow, 117997; Moscow, 119234
A. Belogurov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; Biological Faculty, Moscow State University
Email: vera.knorre@gmail.com
Россия, Moscow, 117997; Moscow, 119234
Дополнительные файлы
